Rat strain differences in the ectopic osteogenic potential of recombinant human BMP adenoviruses

Molecular Therapy

Volumn 8, Issue 5, 2003, Pages 822-829

  Li, Jin Zhong ^a   Li, Hongwei ^a   Dunford, Brad ^a   Holman, David ^a   Beres, Brian ^a   Pittman, Debra D ^b   Hankins, Gerald R ^a   Helm, Gregory A ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b PFIZER INC   (United States)

Author keywords

Adenovirus; BMP4; BMP9; Bone morphogenetic protein; Gene expression; Neutralizing antibody; Rat strain; T cell

Indexed keywords

ADENOVIRUS VECTOR; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 9; CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; CELL CULTURE; CONTROLLED STUDY; GENE EXPRESSION; GENE TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOMODULATION; IMMUNOPHARMACOLOGY; INJECTION SITE; LYMPHOCYTE DIFFERENTIATION; MUSCLE CELL; MUSCLE TISSUE; NONHUMAN; RAT; RAT STRAIN; STRAIN DIFFERENCE; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALIA;

EID: 0348133557     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2003.08.013     Document Type: Article

References (47)

1. Melo, M. E., Gabaglia, C. R., Moudgil, K. D., Sercarz, E. E., and Quinn, A. (2002). Strain-dependent effect of nasal instillation of antigen on the immune response in mice. Isr. Med. Assoc. J. 4: 902-907.
2. Buller, R. E., et al. (2002). A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther. 9: 553-566.
3. Troy Harker, K., Whishaw, and I. Q. (2002). Place and matching-to-place spatial learning affected by rat inbreeding (dark-agouti, Fischer 344) and albinism (Wistar, Sprague-Dawley) but not domestication (wild rat vs. Long-Evans, Fischer-Norway). Behav. Brain Res. 134: 467-477.
4. Butler, N. S., Monick, M. M., Yarovinsky, T. O., Powers, L. S., and Hunninghake, G. W. (2002). Altered IL-4 mRNA stability correlates with Th1 and Th2 bias and susceptibility to hypersensitivity pneumonitis in two inbred strains of mice. J. Immunol. 169: 3700-3709.
5. Drolet, G., Proulx, K., Pearson, D., Rochford, J., and Deschepper, C. F. (2002). Comparisons of behavioral and neurochemical characteristics between WKY, WKHA, and Wistar rat strains. Neuropsychopharmacology 27: 400-409.
6. Tejani-Butt, S., Kluczynski, J., and Pare, W. P. (2003). Strain-dependent modification of behavior following antidepressant treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 27: 7-14.
7. Linkhart, T. A., et al. (1999). Osteoclast formation in bone marrow cultures from two inbred strains of mice with different bone densities. J. Bone Miner. Res. 14: 39-46.
8. Sheng, M. H., et al. (1999). Histomorphometric studies show that bone formation and bone mineral apposition rates are greater in C3H/HeJ (high-density) than C57BL/6J (low-density) mice during growth. Bone 25: 421-429.
9. Shultz, K. L., et al. (2003). Congenic strains of mice for verification and genetic decomposition of quantitative trait loci for femoral bone mineral density. J. Bone Miner. Res. 18: 175-185.
10. Mori, S., et al. (1997). Enhancement of ectopic bone formation in mice with a deficit in Fas-mediated apoptosis. Pathol. Int. 47: 112-116.
11. Sun, Q., and Turner, C. H. (2003). Two inbred rat strains that differ substantially in hip fragility. Calcif. Tissue Int. 15: 15.
12. Wergedal, J. E., Sheng, M. H., Ackert-Bicknell, C. L., Beamer, W. G., and Baylink, D. J. (2002). Mouse genetic model for bone strength and size phenotypes: NZB/B1NJ and RF/J inbred strains. Bone 31: 670-674.
13. Breyer, B., et al. (2001). Adenoviral vector-mediated gene transfer for human gene therapy. Curr. Gene Ther. 1: 149-162.
14. Ferber, D. (2001). Gene therapy. Safer and virus-free? Science 294: 1638-1642.
15. Rajagopalan, S., et al. (2002). Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication. Am. J. Cardiol. 90: 512-516.
16. Wold, W. S., et al. (1999). Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic. Curr. Opin. Immunol. 11: 380-386.
17. Freytag, S. O., et al. (2002). Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 62: 4968-4976.
18. Kuball, J., et al. (2002). Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man. Gene Ther. 9: 833-843.
19. Habib, N. A., et al. (2002). Adenovirus replication-competent vectors (KD1, KD3) complement the cytotoxicity and transgene expression from replication-defective vectors (Ad-GFP, Ad-Luc). Cancer Gene Ther. 9: 651-654.
20. Ghazizadeh, S., Kalish, R. S., and Taichman, L. B. (2003). Immune-mediated loss of transgene expression in skin: implications for cutaneous gene therapy. Mol. Ther. 7: 296-303.
21. Christ, M., et al. (1997). Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response. Immunol. Lett. 57: 19-25.
22. Alden, T. D., et al. (1999). In vivo endochondral bone formation using a bone morphogenetic protein 2 adenoviral vector. Hum. Gene Ther. 10: 2245-2253.
23. Jane, J. A. J., et al. (2002). Ectopic osteogenesis using adenoviral bone morphogenetic protein-4 and -6 gene therapy. Mol. Ther. 6: 464-470.
24. Helm, G. A., et al. (2000). Use of bone morphogenetic protein-9 gene therapy to induce spinal arthrodesis in the rodent. J. Neurosurg. 92: 191-196.
25. Varady, P., et al. (2001). Morphologic analysis of BMP-9 gene therapy-induced osteogenesis. Hum. Gene Ther. 12: 697-710.
26. Li, J. Z., et al. (2001). In vivo activity of recombinant bone morphogenetic protein 9 gutless adenovirus. Mol. Ther. 3: 5228.
27. Li, H. W., Li, J. Z., Amalfitano, A., Hankins, G. R., and Helm, G. A. (2002). Construction of [E1-,E2b-] adenoviral vectors with human bone morphogenetic protein-4 and -6 and their ability to induce ectopic bone formation in rats. Mol. Ther. 5: S373.
28. Duncan, D. B. (1955). Multiple range and multiple F tests. Biometrics 11: 1-42.
29. Van Ginkel, F. W., et al. (1997). Adenoviral gene delivery elicits distinct pulmonary-associated T helper cell responses to the vector and to its transgene. J. Immunol. 159: 685-693.
30. Warren, H. S. (1996). NK cell proliferation and inflammation. Immunol. Cell Biol. 74: 473-480.
31. Gesbert, F., Delespine-Carmagnat, M., and Bertoglio, J. (1998). Recent advances in the understanding of interleukin-2 signal transduction. J. Clin. Immunol. 18: 307-320.
32. Molinier-Frenkel, V., et al. (2000). Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes. J. virol. 74: 7678-7682.
33. Gahery-Segard, H., et al. (1997). Humoral immune response to the capsid components of recombinant adenoviruses: routes of immunization modulate virus-induced Ig subclass shifts. Eur. J. Immunol. 27: 653-659.
34. Cao, B., et al. (2001). The role of receptors in the maturation-dependent adenoviral transduction of myofibers. Gene Ther. 8: 627-637.
35. Kimura, E., et al. (2001). Efficient repetitive gene delivery to skeletal muscle using recombinant adenovirus vector containing the coxsackievirus and adenovirus receptor cDNA. Gene Ther. 8: 20-27.
36. Van Deutekom, J. C., et al. (1999). Extended tropism of an adenoviral vector does not circumvent the maturation-dependent transducibility of mouse skeletal muscle. J. Gene Med. 1: 393-399.
37. Nalbantoglu, J., et al. (2001). Muscle-specific overexpression of the adenovirus primary receptor CAR overcomes low efficiency of gene transfer to mature skeletal muscle. J. Virol. 75: 4276-4282.
38. Nalbantoglu, J., Pari, G., Karpati, G., and Holland, P. C. (1999). Expression of the primary coxsackie and adenovirus receptor is downregulated during skeletal muscle maturation and limits the efficacy of adenovirus-mediated gene delivery to muscle cells. Hum. Gene Ther. 10: 1009-1019.
39. Boden, S. D., et al. (1996). Differential effects and glucocorticoid potentiation of bone morphogenetic protein action during rat osteoblast differentiation in vitro. Endocrinology 137: 3401-3407.
40. Hughes, F. I., Collyer, J., Stanfield, M., and Goodman, S. A. (1995). The effects of bone morphogenetic protein-2, -4, and -6 on differentiation of rat osteoblast cells in vitro. Endocrinology 136: 2671-2677.
41. Yamaguchi, A., et al. (1996). Effects of BMP-2, BMP-4, and BMP-6 on osteoblastic differentiation of bone marrow-derived stromal cell lines, ST2 and MC3T3-G2/PA6. Biochem. Biophys. Res. Commun. 220: 366-371.
42. Hazama, M., Aono, A., Ueno, N., and Fujisawa, Y. (1995). Efficient expression of a heterodimer of bone morphogenetic protein subunits using a baculovirus expression system. Biochem. Biophys. Res. Commun. 209: 859-866.
43. Gysin, R., et al. (2002). Ex vivo gene therapy with stromal cells transduced with a retroviral vector containing the BMP4 gene completely heals critical size calvarial defect in rats. Gene Ther. 9: 991-999.
44. Chen, S., et al. (2001). Suppression of tumor necrosis factor-mediated apoptosis by nuclear factor kappaB-independent bone morphogenetic protein/Smad signaling. J. Biol. Chem. 276: 39259-39263.
45. Liu, Q., and Muruve, D. A. (2003). Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther. 10: 935-940.
46. Croxford, J. L., Feldmann, M., Chernajovsky, Y., and Baker, D. (2001). Different therapeutic outcomes in experimental allergic encephalomyelitis dependent upon the mode of delivery of IL-10: a comparison of the effects of protein, adenoviral or retroviral IL-10 delivery into the central nervous system. J. Immunol. 166: 4124-4130.
47. Farr-Jones, M. A., Parney, I. F., and Petruk, K. C. (1999). Improved technique for establishing short term human brain tumor cultures. J. Neurooncol. 43: 1-10.